APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenzavirus B Infection Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026

19 December 2025213 pages

Choose your research edition.

Industry ResearchInfluenzavirus B Infection Drug Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenzavirus B Infection Drug Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Influenzavirus B Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenzavirus B Infection Drug Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Influenzavirus B Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenzavirus B Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Influenzavirus B Infection Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Influenzavirus B Infection Drug market include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenzavirus B Infection Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenzavirus B Infection Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenzavirus B Infection Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenzavirus B Infection Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenzavirus B Infection Drug Segment by Company

Sanofi

AbbVie Inc

Vectura Group Plc

Vaxart Inc

TSRL Inc

SK Chemicals Co Ltd

Shionogi & Co Ltd

Sanofi Pasteur SA

Romark Laboratories LC

Park Active Molecules

Novavax Inc

Mucosis BV

MedImmune LLC

Medicago Inc

Kineta Inc

Inovio Pharmaceuticals Inc

Green Cross Corp

GlaxoSmithKline Plc

Fujifilm Holdings Corporation

Daiichi Sankyo Company Ltd

ContraFect Corp

Cadila Healthcare Ltd

BioCryst Pharmaceuticals Inc

Aphios Corp

Amarillo Biosciences Inc

Altravax Inc

Adimmune Corp

Influenzavirus B Infection Drug Segment by Type

KIN-1400

GC-3106A

CF-403

APP-309

Others

Influenzavirus B Infection Drug Segment by Application

Clinic

Hospital

Others

Influenzavirus B Infection Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Influenzavirus B Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Influenzavirus B Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Influenzavirus B Infection Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Influenzavirus B Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenzavirus B Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenzavirus B Infection Drug industry.

Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Influenzavirus B Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Influenzavirus B Infection Drug Industry Trends Table 2. Influenzavirus B Infection Drug Industry Drivers Table 3. Influenzavirus B Infection Drug Industry Opportunities and Challenges Table 4. Influenzavirus B Infection Drug Industry Restraints Table 5. Global Influenzavirus B Infection Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Influenzavirus B Infection Drug Revenue Share by Company (2021-2026) Table 7. Global Influenzavirus B Infection Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Influenzavirus B Infection Drug Sales Volume Share by Company (2021-2026) Table 9. Global Influenzavirus B Infection Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Influenzavirus B Infection Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Influenzavirus B Infection Drug Key Company Manufacturing Base & Headquarters Table 12. Global Influenzavirus B Infection Drug Company, Product Type & Application Table 13. Global Influenzavirus B Infection Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of KIN-1400 Table 18. Significant Companies of GC-3106A Table 19. Significant Companies of CF-403 Table 20. Significant Companies of APP-309 Table 21. Significant Companies of Others Table 22. Global Influenzavirus B Infection Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Influenzavirus B Infection Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Influenzavirus B Infection Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Influenzavirus B Infection Drug Sales Volume Share by Type (2021-2026) Table 26. Global Influenzavirus B Infection Drug Sales Volume Share by Type (2027-2032) Table 27. Global Influenzavirus B Infection Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Influenzavirus B Infection Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Influenzavirus B Infection Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Influenzavirus B Infection Drug Sales Value Share by Type (2021-2026) Table 31. Global Influenzavirus B Infection Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Clinic Table 33. Significant Companies of Hospital Table 34. Significant Companies of Others Table 35. Global Influenzavirus B Infection Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Influenzavirus B Infection Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Influenzavirus B Infection Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Influenzavirus B Infection Drug Sales Volume Share by Application (2021-2026) Table 39. Global Influenzavirus B Infection Drug Sales Volume Share by Application (2027-2032) Table 40. Global Influenzavirus B Infection Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Influenzavirus B Infection Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Influenzavirus B Infection Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Influenzavirus B Infection Drug Sales Value Share by Application (2021-2026) Table 44. Global Influenzavirus B Infection Drug Sales Value Share by Application (2027-2032) Table 45. Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Influenzavirus B Infection Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Influenzavirus B Infection Drug Sales Market Share by Region (2021-2026) Table 48. Global Influenzavirus B Infection Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Influenzavirus B Infection Drug Sales Market Share by Region (2027-2032) Table 50. Global Influenzavirus B Infection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Influenzavirus B Infection Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Influenzavirus B Infection Drug Sales Value Share by Region (2021-2026) Table 53. Global Influenzavirus B Infection Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Influenzavirus B Infection Drug Sales Value Share by Region (2027-2032) Table 55. Global Influenzavirus B Infection Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Influenzavirus B Infection Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Influenzavirus B Infection Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Influenzavirus B Infection Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Influenzavirus B Infection Drug Sales Market Share by Country (2021-2026) Table 61. Global Influenzavirus B Infection Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Influenzavirus B Infection Drug Sales Market Share by Country (2027-2032) Table 63. Global Influenzavirus B Infection Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Influenzavirus B Infection Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Influenzavirus B Infection Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Influenzavirus B Infection Drug Sales Value Market Share by Country (2027-2032) Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sanofi Influenzavirus B Infection Drug Product Portfolio Table 71. Sanofi Recent Development Table 72. AbbVie Inc Company Information Table 73. AbbVie Inc Business Overview Table 74. AbbVie Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. AbbVie Inc Influenzavirus B Infection Drug Product Portfolio Table 76. AbbVie Inc Recent Development Table 77. Vectura Group Plc Company Information Table 78. Vectura Group Plc Business Overview Table 79. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio Table 81. Vectura Group Plc Recent Development Table 82. Vaxart Inc Company Information Table 83. Vaxart Inc Business Overview Table 84. Vaxart Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Vaxart Inc Influenzavirus B Infection Drug Product Portfolio Table 86. Vaxart Inc Recent Development Table 87. TSRL Inc Company Information Table 88. TSRL Inc Business Overview Table 89. TSRL Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. TSRL Inc Influenzavirus B Infection Drug Product Portfolio Table 91. TSRL Inc Recent Development Table 92. SK Chemicals Co Ltd Company Information Table 93. SK Chemicals Co Ltd Business Overview Table 94. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 96. SK Chemicals Co Ltd Recent Development Table 97. Shionogi & Co Ltd Company Information Table 98. Shionogi & Co Ltd Business Overview Table 99. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio Table 101. Shionogi & Co Ltd Recent Development Table 102. Sanofi Pasteur SA Company Information Table 103. Sanofi Pasteur SA Business Overview Table 104. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio Table 106. Sanofi Pasteur SA Recent Development Table 107. Romark Laboratories LC Company Information Table 108. Romark Laboratories LC Business Overview Table 109. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio Table 111. Romark Laboratories LC Recent Development Table 112. Park Active Molecules Company Information Table 113. Park Active Molecules Business Overview Table 114. Park Active Molecules Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Park Active Molecules Influenzavirus B Infection Drug Product Portfolio Table 116. Park Active Molecules Recent Development Table 117. Novavax Inc Company Information Table 118. Novavax Inc Business Overview Table 119. Novavax Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novavax Inc Influenzavirus B Infection Drug Product Portfolio Table 121. Novavax Inc Recent Development Table 122. Mucosis BV Company Information Table 123. Mucosis BV Business Overview Table 124. Mucosis BV Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Mucosis BV Influenzavirus B Infection Drug Product Portfolio Table 126. Mucosis BV Recent Development Table 127. MedImmune LLC Company Information Table 128. MedImmune LLC Business Overview Table 129. MedImmune LLC Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. MedImmune LLC Influenzavirus B Infection Drug Product Portfolio Table 131. MedImmune LLC Recent Development Table 132. Medicago Inc Company Information Table 133. Medicago Inc Business Overview Table 134. Medicago Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Medicago Inc Influenzavirus B Infection Drug Product Portfolio Table 136. Medicago Inc Recent Development Table 137. Kineta Inc Company Information Table 138. Kineta Inc Business Overview Table 139. Kineta Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Kineta Inc Influenzavirus B Infection Drug Product Portfolio Table 141. Kineta Inc Recent Development Table 142. Inovio Pharmaceuticals Inc Company Information Table 143. Inovio Pharmaceuticals Inc Business Overview Table 144. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 146. Inovio Pharmaceuticals Inc Recent Development Table 147. Green Cross Corp Company Information Table 148. Green Cross Corp Business Overview Table 149. Green Cross Corp Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Green Cross Corp Influenzavirus B Infection Drug Product Portfolio Table 151. Green Cross Corp Recent Development Table 152. GlaxoSmithKline Plc Company Information Table 153. GlaxoSmithKline Plc Business Overview Table 154. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio Table 156. GlaxoSmithKline Plc Recent Development Table 157. Fujifilm Holdings Corporation Company Information Table 158. Fujifilm Holdings Corporation Business Overview Table 159. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio Table 161. Fujifilm Holdings Corporation Recent Development Table 162. Daiichi Sankyo Company Ltd Company Information Table 163. Daiichi Sankyo Company Ltd Business Overview Table 164. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio Table 166. Daiichi Sankyo Company Ltd Recent Development Table 167. ContraFect Corp Company Information Table 168. ContraFect Corp Business Overview Table 169. ContraFect Corp Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. ContraFect Corp Influenzavirus B Infection Drug Product Portfolio Table 171. ContraFect Corp Recent Development Table 172. Cadila Healthcare Ltd Company Information Table 173. Cadila Healthcare Ltd Business Overview Table 174. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio Table 176. Cadila Healthcare Ltd Recent Development Table 177. BioCryst Pharmaceuticals Inc Company Information Table 178. BioCryst Pharmaceuticals Inc Business Overview Table 179. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio Table 181. BioCryst Pharmaceuticals Inc Recent Development Table 182. Aphios Corp Company Information Table 183. Aphios Corp Business Overview Table 184. Aphios Corp Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Aphios Corp Influenzavirus B Infection Drug Product Portfolio Table 186. Aphios Corp Recent Development Table 187. Amarillo Biosciences Inc Company Information Table 188. Amarillo Biosciences Inc Business Overview Table 189. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio Table 191. Amarillo Biosciences Inc Recent Development Table 192. Altravax Inc Company Information Table 193. Altravax Inc Business Overview Table 194. Altravax Inc Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. Altravax Inc Influenzavirus B Infection Drug Product Portfolio Table 196. Altravax Inc Recent Development Table 197. Adimmune Corp Company Information Table 198. Adimmune Corp Business Overview Table 199. Adimmune Corp Influenzavirus B Infection Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 200. Adimmune Corp Influenzavirus B Infection Drug Product Portfolio Table 201. Adimmune Corp Recent Development Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. Influenzavirus B Infection Drug Distributors List Table 205. Influenzavirus B Infection Drug Customers List Table 206. Research Programs/Design for This Report Table 207. Authors List of This Report Table 208. Secondary Sources Table 209. Primary Sources List of Figures Figure 1. Influenzavirus B Infection Drug Product Image Figure 2. Global Influenzavirus B Infection Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Influenzavirus B Infection Drug Sales (2021-2032) & (K Units) Figure 5. Global Influenzavirus B Infection Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Influenzavirus B Infection Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. KIN-1400 Image Figure 10. GC-3106A Image Figure 11. CF-403 Image Figure 12. APP-309 Image Figure 13. Others Image Figure 14. Global Influenzavirus B Infection Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Influenzavirus B Infection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Influenzavirus B Infection Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Influenzavirus B Infection Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Influenzavirus B Infection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Influenzavirus B Infection Drug Sales Value Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Influenzavirus B Infection Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Influenzavirus B Infection Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Influenzavirus B Infection Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Influenzavirus B Infection Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Influenzavirus B Infection Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Influenzavirus B Infection Drug Sales Value Share by Application (2021-2032) Figure 29. Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Influenzavirus B Infection Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Influenzavirus B Infection Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Influenzavirus B Infection Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Influenzavirus B Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Influenzavirus B Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Influenzavirus B Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Influenzavirus B Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Influenzavirus B Infection Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Influenzavirus B Infection Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Influenzavirus B Infection Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Influenzavirus B Infection Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • KIN-1400
  • GC-3106A
  • CF-403
  • APP-309
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Sanofi
  • AbbVie Inc
  • Vectura Group Plc
  • Vaxart Inc
  • TSRL Inc
  • SK Chemicals Co Ltd
  • Shionogi & Co Ltd
  • Sanofi Pasteur SA
  • Romark Laboratories LC
  • Park Active Molecules
  • Novavax Inc
  • Mucosis BV
  • MedImmune LLC
  • Medicago Inc
  • Kineta Inc
  • Inovio Pharmaceuticals Inc
  • Green Cross Corp
  • GlaxoSmithKline Plc
  • Fujifilm Holdings Corporation
  • Daiichi Sankyo Company Ltd
  • ContraFect Corp
  • Cadila Healthcare Ltd
  • BioCryst Pharmaceuticals Inc
  • Aphios Corp
  • Amarillo Biosciences Inc
  • Altravax Inc
  • Adimmune Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenzavirus B Infection Drug Sales Value (2021-2032)
  4. 1.2.2 Global Influenzavirus B Infection Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Influenzavirus B Infection Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Influenzavirus B Infection Drug Market Dynamics
  1. 2.1 Influenzavirus B Infection Drug Industry Trends
  2. 2.2 Influenzavirus B Infection Drug Industry Drivers
  3. 2.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
  4. 2.4 Influenzavirus B Infection Drug Industry Restraints
3 Influenzavirus B Infection Drug Market by Company
  1. 3.1 Global Influenzavirus B Infection Drug Company Revenue Ranking in 2025
  2. 3.2 Global Influenzavirus B Infection Drug Revenue by Company (2021-2026)
  3. 3.3 Global Influenzavirus B Infection Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Influenzavirus B Infection Drug Average Price by Company (2021-2026)
  5. 3.5 Global Influenzavirus B Infection Drug Company Ranking (2024-2026)
  6. 3.6 Global Influenzavirus B Infection Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Influenzavirus B Infection Drug Company Product Type and Application
  8. 3.8 Global Influenzavirus B Infection Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Influenzavirus B Infection Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Influenzavirus B Infection Drug Market by Type
  1. 4.1 Influenzavirus B Infection Drug Type Introduction
  2. 4.1.1 KIN-1400
  3. 4.1.2 GC-3106A
  4. 4.1.3 CF-403
  5. 4.1.4 APP-309
  6. 4.1.5 Others
  7. 4.2 Global Influenzavirus B Infection Drug Sales Volume by Type
  8. 4.2.1 Global Influenzavirus B Infection Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Influenzavirus B Infection Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Influenzavirus B Infection Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Influenzavirus B Infection Drug Sales Value by Type
  12. 4.3.1 Global Influenzavirus B Infection Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Influenzavirus B Infection Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Influenzavirus B Infection Drug Sales Value Share by Type (2021-2032)
5 Influenzavirus B Infection Drug Market by Application
  1. 5.1 Influenzavirus B Infection Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Influenzavirus B Infection Drug Sales Volume by Application
  6. 5.2.1 Global Influenzavirus B Infection Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Influenzavirus B Infection Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Influenzavirus B Infection Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Influenzavirus B Infection Drug Sales Value by Application
  10. 5.3.1 Global Influenzavirus B Infection Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Influenzavirus B Infection Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Influenzavirus B Infection Drug Sales Value Share by Application (2021-2032)
6 Influenzavirus B Infection Drug Regional Sales and Value Analysis
  1. 6.1 Global Influenzavirus B Infection Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenzavirus B Infection Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Influenzavirus B Infection Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Influenzavirus B Infection Drug Sales by Region (2027-2032)
  5. 6.3 Global Influenzavirus B Infection Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Influenzavirus B Infection Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Influenzavirus B Infection Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Influenzavirus B Infection Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Influenzavirus B Infection Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Influenzavirus B Infection Drug Sales Value (2021-2032)
  12. 6.6.2 North America Influenzavirus B Infection Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Influenzavirus B Infection Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Influenzavirus B Infection Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Influenzavirus B Infection Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Influenzavirus B Infection Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Influenzavirus B Infection Drug Sales Value (2021-2032)
  21. 6.9.2 South America Influenzavirus B Infection Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Influenzavirus B Infection Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Influenzavirus B Infection Drug Sales Value Share by Country, 2025 VS 2032
7 Influenzavirus B Infection Drug Country-level Sales and Value Analysis
  1. 7.1 Global Influenzavirus B Infection Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Influenzavirus B Infection Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Influenzavirus B Infection Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Influenzavirus B Infection Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Influenzavirus B Infection Drug Sales by Country (2027-2032)
  6. 7.4 Global Influenzavirus B Infection Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Influenzavirus B Infection Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Influenzavirus B Infection Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Influenzavirus B Infection Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Influenzavirus B Infection Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Influenzavirus B Infection Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 AbbVie Inc
  8. 8.2.1 AbbVie Inc Company Information
  9. 8.2.2 AbbVie Inc Business Overview
  10. 8.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
  12. 8.2.5 AbbVie Inc Recent Developments
  13. 8.3 Vectura Group Plc
  14. 8.3.1 Vectura Group Plc Company Information
  15. 8.3.2 Vectura Group Plc Business Overview
  16. 8.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
  18. 8.3.5 Vectura Group Plc Recent Developments
  19. 8.4 Vaxart Inc
  20. 8.4.1 Vaxart Inc Company Information
  21. 8.4.2 Vaxart Inc Business Overview
  22. 8.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
  24. 8.4.5 Vaxart Inc Recent Developments
  25. 8.5 TSRL Inc
  26. 8.5.1 TSRL Inc Company Information
  27. 8.5.2 TSRL Inc Business Overview
  28. 8.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
  30. 8.5.5 TSRL Inc Recent Developments
  31. 8.6 SK Chemicals Co Ltd
  32. 8.6.1 SK Chemicals Co Ltd Company Information
  33. 8.6.2 SK Chemicals Co Ltd Business Overview
  34. 8.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
  36. 8.6.5 SK Chemicals Co Ltd Recent Developments
  37. 8.7 Shionogi & Co Ltd
  38. 8.7.1 Shionogi & Co Ltd Company Information
  39. 8.7.2 Shionogi & Co Ltd Business Overview
  40. 8.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
  42. 8.7.5 Shionogi & Co Ltd Recent Developments
  43. 8.8 Sanofi Pasteur SA
  44. 8.8.1 Sanofi Pasteur SA Company Information
  45. 8.8.2 Sanofi Pasteur SA Business Overview
  46. 8.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
  48. 8.8.5 Sanofi Pasteur SA Recent Developments
  49. 8.9 Romark Laboratories LC
  50. 8.9.1 Romark Laboratories LC Company Information
  51. 8.9.2 Romark Laboratories LC Business Overview
  52. 8.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
  54. 8.9.5 Romark Laboratories LC Recent Developments
  55. 8.10 Park Active Molecules
  56. 8.10.1 Park Active Molecules Company Information
  57. 8.10.2 Park Active Molecules Business Overview
  58. 8.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
  60. 8.10.5 Park Active Molecules Recent Developments
  61. 8.11 Novavax Inc
  62. 8.11.1 Novavax Inc Company Information
  63. 8.11.2 Novavax Inc Business Overview
  64. 8.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
  66. 8.11.5 Novavax Inc Recent Developments
  67. 8.12 Mucosis BV
  68. 8.12.1 Mucosis BV Company Information
  69. 8.12.2 Mucosis BV Business Overview
  70. 8.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
  72. 8.12.5 Mucosis BV Recent Developments
  73. 8.13 MedImmune LLC
  74. 8.13.1 MedImmune LLC Company Information
  75. 8.13.2 MedImmune LLC Business Overview
  76. 8.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
  78. 8.13.5 MedImmune LLC Recent Developments
  79. 8.14 Medicago Inc
  80. 8.14.1 Medicago Inc Company Information
  81. 8.14.2 Medicago Inc Business Overview
  82. 8.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
  84. 8.14.5 Medicago Inc Recent Developments
  85. 8.15 Kineta Inc
  86. 8.15.1 Kineta Inc Company Information
  87. 8.15.2 Kineta Inc Business Overview
  88. 8.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
  90. 8.15.5 Kineta Inc Recent Developments
  91. 8.16 Inovio Pharmaceuticals Inc
  92. 8.16.1 Inovio Pharmaceuticals Inc Company Information
  93. 8.16.2 Inovio Pharmaceuticals Inc Business Overview
  94. 8.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  96. 8.16.5 Inovio Pharmaceuticals Inc Recent Developments
  97. 8.17 Green Cross Corp
  98. 8.17.1 Green Cross Corp Company Information
  99. 8.17.2 Green Cross Corp Business Overview
  100. 8.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
  102. 8.17.5 Green Cross Corp Recent Developments
  103. 8.18 GlaxoSmithKline Plc
  104. 8.18.1 GlaxoSmithKline Plc Company Information
  105. 8.18.2 GlaxoSmithKline Plc Business Overview
  106. 8.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
  108. 8.18.5 GlaxoSmithKline Plc Recent Developments
  109. 8.19 Fujifilm Holdings Corporation
  110. 8.19.1 Fujifilm Holdings Corporation Company Information
  111. 8.19.2 Fujifilm Holdings Corporation Business Overview
  112. 8.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
  114. 8.19.5 Fujifilm Holdings Corporation Recent Developments
  115. 8.20 Daiichi Sankyo Company Ltd
  116. 8.20.1 Daiichi Sankyo Company Ltd Company Information
  117. 8.20.2 Daiichi Sankyo Company Ltd Business Overview
  118. 8.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
  120. 8.20.5 Daiichi Sankyo Company Ltd Recent Developments
  121. 8.21 ContraFect Corp
  122. 8.21.1 ContraFect Corp Company Information
  123. 8.21.2 ContraFect Corp Business Overview
  124. 8.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
  126. 8.21.5 ContraFect Corp Recent Developments
  127. 8.22 Cadila Healthcare Ltd
  128. 8.22.1 Cadila Healthcare Ltd Company Information
  129. 8.22.2 Cadila Healthcare Ltd Business Overview
  130. 8.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
  132. 8.22.5 Cadila Healthcare Ltd Recent Developments
  133. 8.23 BioCryst Pharmaceuticals Inc
  134. 8.23.1 BioCryst Pharmaceuticals Inc Company Information
  135. 8.23.2 BioCryst Pharmaceuticals Inc Business Overview
  136. 8.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
  138. 8.23.5 BioCryst Pharmaceuticals Inc Recent Developments
  139. 8.24 Aphios Corp
  140. 8.24.1 Aphios Corp Company Information
  141. 8.24.2 Aphios Corp Business Overview
  142. 8.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
  144. 8.24.5 Aphios Corp Recent Developments
  145. 8.25 Amarillo Biosciences Inc
  146. 8.25.1 Amarillo Biosciences Inc Company Information
  147. 8.25.2 Amarillo Biosciences Inc Business Overview
  148. 8.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
  150. 8.25.5 Amarillo Biosciences Inc Recent Developments
  151. 8.26 Altravax Inc
  152. 8.26.1 Altravax Inc Company Information
  153. 8.26.2 Altravax Inc Business Overview
  154. 8.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  155. 8.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
  156. 8.26.5 Altravax Inc Recent Developments
  157. 8.27 Adimmune Corp
  158. 8.27.1 Adimmune Corp Company Information
  159. 8.27.2 Adimmune Corp Business Overview
  160. 8.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2021-2026)
  161. 8.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
  162. 8.27.5 Adimmune Corp Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenzavirus B Infection Drug Value Chain Analysis
  2. 9.1.1 Influenzavirus B Infection Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenzavirus B Infection Drug Sales Mode & Process
  6. 9.2 Influenzavirus B Infection Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenzavirus B Infection Drug Distributors
  9. 9.2.3 Influenzavirus B Infection Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst